Literature DB >> 22990721

Dopamine transporter imaging in clinically unclear cases of parkinsonism and the importance of scans without evidence of dopaminergic deficit (SWEDDs).

Marco A T Utiumi1, André C Felício, Conrado R Borges, Vera L Braatz, Sheyla A S Rezende, Renato P Munhoz, Rodrigo A Bressan, Henrique B Ferraz, Hélio A G Teive.   

Abstract

UNLABELLED: The clinical diagnosis of Parkinson's disease (PD) is susceptible to misdiagnosis, especially in the earlier stages of the disease. Recently, in vivo imaging techniques assessing the presynaptic dopamine transporter (DAT) have emerged as a useful tool in PD diagnosis, improving its accuracy.
OBJECTIVE: It was to illustrate the clinical usefulness of a brain single-photon emission computed tomography (SPECT) DAT ligand, and highlight relevant aspects of scans without evidence of dopaminergic deficit (SWEDDs) in this context. CASES: We described four representative patients with clinically unclear parkinsonian syndromes who underwent [(99m)Tc]-TRODAT-1 SPECT and reviewed the clinical implications.
CONCLUSION: DAT-SPECT is an important, cost-effective, technique for the differential diagnosis of parkinsonian syndromes. Additionally, SWEDD cases present clinical and paraclinical peculiarities that may retrospectively identify them as essential/dystonic tremor. The lack of histopathological data limits further conclusions.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22990721     DOI: 10.1590/s0004-282x2012000900004

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  8 in total

1.  Screening for dopa-responsive dystonia in patients with Scans Without Evidence of Dopaminergic Deficiency (SWEDD).

Authors:  Anna De Rosa; Claudia Carducci; Carla Carducci; Silvio Peluso; Maria Lieto; Andrea Mazzella; Francesco Saccà; Vincenzo Brescia Morra; Sabina Pappatà; Vincenzo Leuzzi; Giuseppe De Michele
Journal:  J Neurol       Date:  2014-09-03       Impact factor: 4.849

Review 2.  Unexpected (123I)FP-CIT SPECT findings: SWIDD, SWEDD and all DAT.

Authors:  Balestrino Roberta; Barone Paolo; Filippi Massimo; Erro Roberto
Journal:  J Neurol       Date:  2021-09-18       Impact factor: 6.682

3.  Combined visual and semi-quantitative assessment of 123I-FP-CIT SPECT for the diagnosis of dopaminergic neurodegenerative diseases.

Authors:  Jun Ueda; Hajime Yoshimura; Keiji Shimizu; Megumu Hino; Nobuo Kohara
Journal:  Neurol Sci       Date:  2017-04-07       Impact factor: 3.307

4.  High Prevalence of Early Parkinson's Disease in Patients With Subtle Parkinsonian Signs.

Authors:  Shoichi Sasaki
Journal:  Front Neurol       Date:  2021-07-09       Impact factor: 4.003

5.  Interpreting 123I-ioflupane dopamine transporter scans using hybrid scores.

Authors:  Kenneth J Nichols; Brandon Chen; Maria B Tomas; Christopher J Palestro
Journal:  Eur J Hybrid Imaging       Date:  2018-05-21

6.  Dopamine transporter imaging in psychogenic parkinsonism and neurodegenerative parkinsonism with psychogenic overlay: a report of three cases.

Authors:  Chizoba C Umeh; Zsolt Szabo; Gregory M Pontone; Zoltan Mari
Journal:  Tremor Other Hyperkinet Mov (N Y)       Date:  2013-09-10

7.  Dopamine transporter imaging using 99mTc-TRODAT-1 SPECT in Parkinson's disease.

Authors:  Edson Bor-Seng-Shu; Andre C Felicio; Pedro Braga-Neto; Ilza Rosa Batista; Wellingson Silva Paiva; Daniel Ciampi de Andrade; Manoel Jacobsen Teixeira; Luis Augusto Franco de Andrade; Orlando Graziani Povoas Barsottini; Ming Chi Shih; Rodrigo A Bressan; Henrique Ballalai Ferraz
Journal:  Med Sci Monit       Date:  2014-08-11

8.  Importance of (123)I-ioflupane SPECT and Myocardial MIBG Scintigraphy to Determine the Candidate of Deep Brain Stimulation for Parkinson's Disease.

Authors:  Takashi Asahi; Daina Kashiwazaki; Tatsuya Yoneyama; Kyo Noguchi; Satoshi Kuroda
Journal:  Neurol Med Chir (Tokyo)       Date:  2016-01-20       Impact factor: 1.742

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.